Similar articles

• Presumption of innocence: FDA's authority to regulate the specifics of prescription drug labeling and the preemption debate.

  Dorfman HL, Quinn VM, Brophy EA. Dorfman HL, et al. Food Drug Law J. 2006;61(4):585-622. Food Drug Law J. 2006. PMID: 17180765 No abstract available.
• Bolstering the FDA's drug-safety authority.

  Schultz WB. Schultz WB. N Engl J Med. 2007 Nov 29;357(22):2217-9. doi: 10.1056/NEJMp078212. N Engl J Med. 2007. PMID: 18046024 No abstract available.
• FDA attempting to overcome major roadblocks in monitoring drug safety.

  Zielinski SL. Zielinski SL. J Natl Cancer Inst. 2005 Jun 15;97(12):872-3. doi: 10.1093/jnci/97.12.872. J Natl Cancer Inst. 2005. PMID: 15956645 No abstract available.
• Preventing postmarketing changes in recommended doses and marketing withdrawals.

  Peck C. Peck C. Ernst Schering Res Found Workshop. 2007;(59):209-16. doi: 10.1007/978-3-540-49529-1_16. Ernst Schering Res Found Workshop. 2007. PMID: 17117726 Review.
• Pharmaceutical industry perspective on risk evaluation and mitigation strategies: manufacturer take heed.

  Nicholson S, Peterson J, Yektashenas B. Nicholson S, et al. Expert Opin Drug Saf. 2012 Mar;11(2):299-314. doi: 10.1517/14740338.2012.650689. Epub 2012 Jan 10. Expert Opin Drug Saf. 2012. PMID: 22233294 Review.